Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)

SHA:603520 Revenue

Zhejiang Starry Pharmaceutical had revenue of 594.01M CNY in the quarter ending September 30, 2026, with 32.81% growth. This brings the company's total for the last twelve months to 2.61B, up 9.13% year-over-year. In the year 2025, Zhejiang Starry Pharmaceutical had annual revenue of 2.45B with 4.07% growth. That makes Zhejiang Starry Pharmaceutical the 12,782nd largest company in the world by revenue and 2,219th in China.

• Revenue (ttm): 2.61B
• Revenue Growth: +9.13%
• P/S Ratio: 1.31
• Revenue / Employee: 1.37M
• Employees: 1,905
• Market Cap: 3.40B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Contrast Agent 2.13B 95.5%
• CMO/CDMO 40.54M 1.8%
• Quinolone 36.25M 1.6%
• Others 22.97M 1.0%

By Geography

Chart

• China 1.29B 57.7%
• Foreign 944.90M 42.3%

Fiscal year ended Dec 31, 2025 See the full SHA:603520 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.45B	95.55M	4.07%
Dec 31, 2024	2.35B	154.24M	7.02%
Dec 31, 2023	2.20B	64.75M	3.04%
Dec 31, 2022	2.13B	131.32M	6.57%
Dec 31, 2021	2.00B	632.83M	46.29%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error